Arecor Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Arecor Limited - overview
Established
2007
Location
Cambridge, England, UK
Primary Industry
Biotechnology
About
Based in Cambridge, UK, and founded in 2007 Arecor Limited enhances the existing therapeutic medicines which help in bringing safer and more effective treatments to patients. In June 2021, the firm raised an amount of PIPE funding from returning investor Calculus Capital. The PIPE deal gives the company a market capitalization of approximately GBP 66. 03 million.
As of 2021, the company is headed by Sarah Howell as CEO. The company offers Arestat technology platform which delivers differentiation in the form of products. The products of the firm include AT247 the ultra-rapid-acting insulin and AT278 the ultra-concentrated rapid-acting insulin. Additionally, the firm provides differentiated biosimilars with IP protection, intravenous to subcutaneous switch, and lyophilised powder to liquid switch.
Furthermore, it offers high-concentration antibodies, superior peptides, and thermostable vaccines and therapeutics. The June 2021, investment by Calculus Capital may help to progress the company’s lead diabetes products, develop and expand its pipeline of specialty hospital Ready-To-Use and Ready-To-Administer products and build the team, as well as bolster working capital and strengthen the balance sheet.
Current Investors
O2h Ventures, Albion Capital, Calculus Capital
Primary Industry
Biotechnology
Sub Industries
Biopolymers, Biopharmaceuticals
Website
www.arecor.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Arecor Limited - financials
| Fiscal Year Ended | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue (USD) | 1,158,000 | 1,352,000 | - | - | - |
| % Revenue Growth (YoY) | - | 16.8% | - | - | - |
| EBITDA (USD) | (5,612,000) | (8,509,000) | - | - | - |
| Operating Income (USD) | (5,781,000) | (8,729,000) | - | - | - |
| Operating Margin | (499.2%) | (645.6%) | - | - | - |
| % EBITDA Margin | (484.6%) | (629.4%) | - | - | - |
| NET Income (USD) | (5,962,000) | (7,791,000) | - | - | - |
| % Net Margin | (514.9%) | (576.3%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.